Short answer
Esperion Therapeutics, Inc. (ESPR) filed its Q1 2026 10-Q quarterly report on May 8, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $80M (up 23.2% year over year) with net income of −$25M.
Q1 2026 key financials · XBRL
- Revenue
- $80M
- +23.2% YoY
- Net income
- −$25M
- +37.7% YoY
- Operating margin
- -8.2%
- EPS (diluted)
- −$0.10
- +52.4% YoY
Source: XBRL data from the Esperion Therapeutics, Inc. (ESPR) Q1 2026 10-Q on SEC EDGAR. USD.
Esperion Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $80.1M, up from $65.0M YoY, including product sales $43.4M and collaboration revenue $36.7M
- Operating loss $6.6M versus $22.1M YoY; net loss $25.2M versus $40.5M
- Product sales increased $8.5M on NEXLETOL and NEXLIZET prescription growth
- Collaboration revenue increased $6.6M from royalty sales growth in partner territories
- Corstasis acquisition funded with $25.0M additional term loans and $75.0M upfront cash payment
Risk Factors
- New merger risk triggered by May 1, 2026 agreement: failure to close could require a $34,154,539 termination fee
- Most material financial update: April 2 amendment added $25 million of term loans, carrying 9.75% cash or 11.75% PIK interest
- Regulatory risk: HSR Act approval may impose conditions, delay closing, or prevent the Merger
- Operational risk: Corstasis integration may disrupt operations and delay Enbumyst commercialization
- Liquidity risk: Credit Agreement requires minimum liquidity of $50.0 million
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Esperion Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.